X

Drug Profile

SPRC AB01

Alternative Names: SPRC-AB01; Sybryx; Tobramycin solution for nasal inhalation

Latest Information Update: 23 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Naryx Pharma
Class Aminoglycosides; Anti-infectives; Antibacterials; Antibronchitics; Small molecules
Mechanism of Action Protein synthesis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Sinusitis

Most Recent Events

11 Sep 2013 Discontinued - Phase-II for Sinusitis in USA (Inhalation)
27 Nov 2007 Naryx Pharma completed enrolment into its phase IIb trial for chronic sinusitis in USA
17 Apr 2007 SPRC AB01 receives fast track status for chronic sinusitis in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com